EMA/29056/2024

European Medicines Agency decision

P/0044/2024

of 15 February 2024

on the acceptance of a modification of an agreed paediatric investigation plan for pariglasgene brecaparvovec (DTX401) (EMEA-002734-PIP01-19-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0044/2024

of 15 February 2024

on the acceptance of a modification of an agreed paediatric investigation plan for pariglasgene brecaparvovec (DTX401) (EMEA-002734-PIP01-19-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0278/2021 issued on 8 July 2021,

Having regard to the application submitted by Ultragenyx Germany GmbH on 11 September 2023 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 15 December 2023, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for pariglasgene brecaparvovec (DTX401), concentrate and diluent for solution for infusion, intravenous use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Ultragenyx Germany GmbH, Rahel-Hirsch-Str.10, 10557 - Berlin, Germany.

EMA/PDCO/420946/2023
Amsterdam, 15 December 2023

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-002734-PIP01-19-M01

Scope of the application

Active substance(s):

Pariglasgene brecaparvovec (DTX401)

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of glycogen storage disease type Ia

Pharmaceutical form(s):

Concentrate and diluent for solution for infusion

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

Ultragenyx Germany GmbH

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Ultragenyx Germany GmbH submitted to the European Medicines Agency on 11 September 2023 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0278/2021 issued on 8 July 2021.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 16 October 2023.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

   The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Treatment of glycogen storage disease type Ia

The waiver applies to:

- the paediatric population from birth to less than 2 years of age;
- concentrate and diluent for solution for infusion, intravenous use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2. Paediatric investigation plan

2.1. Condition:

Treatment of glycogen storage disease type Ia

2.1.1. Indication(s) targeted by the PIP

Treatment of glycogen storage disease type Ia

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 years to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Concentrate and diluent for solution for infusion

2.1.4. Measures

Area	**Description**
Quality-related studies	Not applicable
Non-clinical studies	**Study 1** CRL Study Number: 20282036 Juvenile animal efficacy study to evaluate the potential loss of vector expression and pharmacological effects at various ages to better inform paediatric dose selection
Clinical studies	**Study 2** DTX401-CL301 Randomized, double-blind, placebo- controlled Phase 3 clinical study to evaluate the efficacy and safety of DTX401 in patients 8 years of age and older with GSDIa. In particular the reduction or elimination of dependence on exogenous glucose replacement

	therapy and the effect of DTX401 on glucose control will be evaluated **Study 3** DTX401-CL302 Open-label, non-comparative study to determine the efficacy and confirm the safety of DTX401 in pediatric patients with GSDIa aged 2 years to <8 years of age, evaluating the efficacy of DTX401 in providing normal G6Pase activity, and thereby reducing dependence on exogenous glucose replacement therapy needed to maintain glucose control.
Extrapolation, modelling and simulation studies	Not applicable
Other studies	Not applicable
Other measures	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By March 2028
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

The product is not authorised anywhere in the European Community.